Skip to main content

Table 2 Response rates for patients without cirrhosis

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Genotype Treatment Duration (weeks) SVR (%) Trials
1 Telaprevir + Peginterferon-alpha + Ribavirin 12 + 12 or 12 + 36 75 ADVANCE
Harvoni 12 98 ION
Olysio + Sovaldi 12 95 COSMOS
Viekira Pak + Ribavirin 12 96 SAPPHIRE
Sofosbuvir + Peginterferon + Ribavirin 12 92 NEUTRINO
2 Peginterferon + Ribavirin (Treatment-naïve) 24 81 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 12 97 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 90 FUSION
16 92 FUSION
3 Peginterferon + Ribavirin (Treatment-naïve) 24 81 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 24 93 VALENCE
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 37 FUSION
16 63 FUSION